Contact this trialFirst, we need to learn more about you.
Chemotherapy
Lapatinib + Chemotherapy for Gastrointestinal Cancer
Recruiting1 awardPhase 3
London, Ontario
This trial will enroll patients with cancer of the stomach, esophagus, or gastro-esophageal junction whose tumors have amplification of the ErbB2 (HER2) gene. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.